Neurocrine Biosciences NBIX
NASDAQ NBIX
$174.41 +5.27 (+3.12%)
At close: Nov 11, 2026 · 4:00 PM EST

Neurocrine Biosciences (NBIX) Amortization - Intangibles (2025 - 2026)

Updated

Neurocrine Biosciences' Amortization - Intangibles was $35 million in Q3 2026, compared with $1 million a year earlier and up 113.4% from the prior quarter.

Analysis

Neurocrine Biosciences (NBIX) Amortization - Intangibles (2025 - 2026) Analysis & Trends

On a trailing twelve-month basis, Neurocrine Biosciences' Amortization - Intangibles was $53.4 million through Sep 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Neurocrine Biosciences 17.13 Bn 13.21 Bn 1.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 35.00 Mn
Jun 30, 2026 16.40 Mn
Sep 30, 2025 1.00 Mn
Jun 30, 2025 1.00 Mn
API Access

Neurocrine Biosciences Amortization - Intangibles API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-intangibles&ticker=NBIX&period=max&api_key=YOUR_API_KEY